Aptorum Group Limited Class A Ordinary Shares (APM)

FairStock Score: 68/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I am a value investor, so I start with business quality and a margin of safety. Aptorum is a clinical-stage biopharmaceutical company with one employee and two early Phase 1 candidates, SACT-1 and ALS-4. There is no commercial product and no meaningful revenue in the data, so I see no durable competitive moat—only the hope of clinical and regulatory success. The balance sheet is not heavily levered: debt-to-equity is 0.25, and beta is 0.09. But the income and cash profile are weak. FairStock’s calculations at the 2026-07-27 close of $8.41 show a market cap of only $7.4 million, a negative P/E of -44.26, P/B of 2.96, ROE of -10.79%, ROCE of -6.52%, and a negative FCF yield of -12.5%. Trailing free cash flow was -$928,849. The Piotroski F-Score is 2/9 and Altman Z-Score is -4.68, both warning signs. Aptorum does not qualify for a Lynch category because it has only 0 years of filed results and needs 3. The 52-week range of $0.65 to $12.24 shows how speculative the equity has been. Growth is entirely milestone-dependent, not revenue-driven. A FairStock Score of 68/100 may capture optionality, but Graham would demand proof of earnings and assets. I would treat this as a speculative pipeline bet, not a proven business.

In plain English: Aptorum Group is a tiny company testing early-stage drugs for cancer and infections. It has no meaningful revenue, loses money, and burns cash, so the business looks weak and unproven. At the 2026-07-27 close of $8.41 and a $7.4 million market value, the price does not look clearly cheap given the losses and risks.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-07-27 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer